BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Hoog MLA, Venekamp RP, Meijer A, Sanders EAM, Bruijning-Verhagen PCJL. Inactivated influenza vaccine does not reduce all cause respiratory illness in children with pre-existing medical conditions. Vaccine 2020;38:3397-403. [PMID: 31859200 DOI: 10.1016/j.vaccine.2019.11.086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Naber SK, Bruijning-Verhagen PCJL, de Hoog MLA, van Giessen A. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands. Vaccine 2020;38:3387-96. [PMID: 32115297 DOI: 10.1016/j.vaccine.2020.01.057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Asogwa OA, de Hoog MLA, Bruijning-Verhagen PCJI. Impact of 7-valent versus 10-valent pneumococcal conjugate vaccines on primary care consultations across various age groups in the Netherlands, 5 years after the switch: A time-series analysis. Vaccine 2021:S0264-410X(21)01533-4. [PMID: 34969546 DOI: 10.1016/j.vaccine.2021.11.059] [Reference Citation Analysis]
3 Caini S, Paget J, Spreeuwenberg P, Korevaar JC, Meijer A, Hooiveld M. Impact of influenza vaccination in the Netherlands, 2007-2016: Vaccinees consult their general practitioner for clinically diagnosed influenza, acute respiratory infections, and pneumonia more often than non-vaccinees. PLoS One 2021;16:e0249883. [PMID: 34048429 DOI: 10.1371/journal.pone.0249883] [Reference Citation Analysis]
4 Boravleva EY, Lunitsin AV, Kaplun AP, Bykova NV, Krasilnikov IV, Gambaryan AS. Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge. Biochemistry (Mosc) 2020;85:553-66. [PMID: 32571185 DOI: 10.1134/S0006297920050041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]